Vassilios G Athyros

Summary

Affiliation: Aristotle University of Thessaloniki
Country: Greece

Publications

  1. pmc Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review
    Konstantinos Tziomalos
    Atherosclerosis and Metabolic Syndrome Units, 2nd Prop Department of Internal Medicine, Aristotelian University, Hippokration Hospital, Thessaloniki, Greece
    Int J Nanomedicine 1:129-47. 2006
  2. ncbi request reprint Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview
    Niki Katsiki
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece, 44, Tsimiski Street, Thessaloniki, 54623, Greece
    Curr Vasc Pharmacol 12:627-41. 2014
  3. pmc Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters
    Vasilios G Athyros
    Atherosclerosis Unit, Department of Internal Medicine, School of Medicine, Aristotelian University of Thessaloniki, Greece
    Open Cardiovasc Med J 6:122-5. 2012
  4. pmc Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment
    Vasilios G Athyros
    Second Propedeutic Department of Internal Medicine, Aristotle University, Hippocration Hospital, Thessaloniki, Greece
    Open Cardiovasc Med J 5:24-34. 2011
  5. pmc Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients
    Vasilios G Athyros
    Atherosclerosis and Metabolic Syndrome Units, 2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, 49 Konstantinoupoleos St, Thessaloniki 546 42, Greece
    Open Cardiovasc Med J 1:8-14. 2007
  6. ncbi request reprint Atorvastatin: safety and tolerability
    Vasilios G Athyros
    Aristotle University of Thessaloniki, Hippokration Hospital, Medical School, Second Propedeutic Department of Internal Medicine, 15 Marmara St, Thessaloniki 551 32, Greece
    Expert Opin Drug Saf 9:667-74. 2010
  7. ncbi request reprint Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study
    Vasilios G Athyros
    Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 20:1691-1701. 2004
  8. ncbi request reprint Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study
    Vasilios G Athyros
    Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, 49 Konstantinoupoleos St, Thessaloniki, 546 42, Greece
    Platelets 16:65-71. 2005
  9. ncbi request reprint The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study
    V G Athyros
    Atherosclerosis and Metabolic Syndrome Units, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Diabetes Obes Metab 7:397-405. 2005
  10. ncbi request reprint The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions
    Vasilios G Athyros
    Atherosclerosis and Metabolic Syndrome Units, 2nd Prop Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 21:1157-9. 2005

Detail Information

Publications79

  1. pmc Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review
    Konstantinos Tziomalos
    Atherosclerosis and Metabolic Syndrome Units, 2nd Prop Department of Internal Medicine, Aristotelian University, Hippokration Hospital, Thessaloniki, Greece
    Int J Nanomedicine 1:129-47. 2006
    ....
  2. ncbi request reprint Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview
    Niki Katsiki
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece, 44, Tsimiski Street, Thessaloniki, 54623, Greece
    Curr Vasc Pharmacol 12:627-41. 2014
    ..Furthermore, we discuss the impact of frequently prescribed drugs (e.g. hypolipidaemic agents) on these variables. These effects may need to be taken into consideration when treating MetS patients. ..
  3. pmc Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters
    Vasilios G Athyros
    Atherosclerosis Unit, Department of Internal Medicine, School of Medicine, Aristotelian University of Thessaloniki, Greece
    Open Cardiovasc Med J 6:122-5. 2012
    ....
  4. pmc Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment
    Vasilios G Athyros
    Second Propedeutic Department of Internal Medicine, Aristotle University, Hippocration Hospital, Thessaloniki, Greece
    Open Cardiovasc Med J 5:24-34. 2011
    ....
  5. pmc Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients
    Vasilios G Athyros
    Atherosclerosis and Metabolic Syndrome Units, 2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, 49 Konstantinoupoleos St, Thessaloniki 546 42, Greece
    Open Cardiovasc Med J 1:8-14. 2007
    ..Little is known about the potential of statin-induced high-density lipoprotein cholesterol (HDL-C) increase to improve renal function in coronary heart disease (CHD) patients...
  6. ncbi request reprint Atorvastatin: safety and tolerability
    Vasilios G Athyros
    Aristotle University of Thessaloniki, Hippokration Hospital, Medical School, Second Propedeutic Department of Internal Medicine, 15 Marmara St, Thessaloniki 551 32, Greece
    Expert Opin Drug Saf 9:667-74. 2010
    ..Therefore, the safety and tolerability of atorvastatin is of paramount importance...
  7. ncbi request reprint Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study
    Vasilios G Athyros
    Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 20:1691-1701. 2004
    ....
  8. ncbi request reprint Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study
    Vasilios G Athyros
    Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, 49 Konstantinoupoleos St, Thessaloniki, 546 42, Greece
    Platelets 16:65-71. 2005
    ..Aggressive statin use in the absence of ASA also substantially reduced cardiovascular events. Treatment with ASA in the absence of statin use reduced clinical events in comparison to patients not treated with either drug...
  9. ncbi request reprint The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study
    V G Athyros
    Atherosclerosis and Metabolic Syndrome Units, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Diabetes Obes Metab 7:397-405. 2005
    ..Limited information is available about the prevalence of MetS, as defined by the NCEP ATP III, in Europe, especially in Greece...
  10. ncbi request reprint The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions
    Vasilios G Athyros
    Atherosclerosis and Metabolic Syndrome Units, 2nd Prop Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 21:1157-9. 2005
    ....
  11. ncbi request reprint Targeting vascular risk in patients with metabolic syndrome but without diabetes
    Vasilios G Athyros
    Atherosclerosis and Metabolic Syndrome Units, Aristotelian University, 55132 Thessaloniki, Greece
    Metabolism 54:1065-74. 2005
    ..Atorvastatin and combination treatment were more effective than fenofibrate alone in reducing CRP levels...
  12. ncbi request reprint Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia
    Vasilios G Athyros
    Lipid Out patient Clinic, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Diabetes Care 25:1198-202. 2002
    ..This study evaluated the effect of a atorvastatin-fenofibrate combination on lipid profile, in comparison to each drug alone, in patients with type 2 diabetes and combined hyperlipidemia (CHL)...
  13. ncbi request reprint Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study
    Vasilios G Athyros
    Atherosclerosis and Metabolic Syndrome Units, 2nd Prop Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Hellenic J Cardiol 46:380-6. 2005
    ..There are no data concerning the degree of awareness, treatment and control of the metabolic syndrome (MetS) and its components or associated vascular risk in the general population...
  14. doi request reprint Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients
    Vasilios G Athyros
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece
    Am J Cardiol 101:483-5. 2008
    ..In conclusion, the combination of ezetimibe plus atorvastatin 10 mg twice a week might be a therapeutic option for high-risk patients intolerant to daily statin monotherapy...
  15. ncbi request reprint Pleiotropic effects of statins--clinical evidence
    Vasilios G Athyros
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, HippocrationHospital, Thessaloniki, Greece
    Curr Pharm Des 15:479-89. 2009
    ....
  16. ncbi request reprint Dyslipidemia as a risk factor for ischemic stroke
    Konstantinos Tziomalos
    Department of Clinical Biochemistry Vascular Prevention Clinic, Royal Free Campus, University College London Medical School, University College London UCL, London, UK
    Curr Top Med Chem 9:1291-7. 2009
    ..Nevertheless, more trials are required to identify which patients with stroke but without CHD will benefit more from statin treatment...
  17. ncbi request reprint Statins for the prevention of first or recurrent stroke
    Vasilios G Athyros
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece
    Curr Vasc Pharmacol 6:124-33. 2008
    ..Thus, statins may be beneficial to both the heart and the brain...
  18. ncbi request reprint Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
    Vasilios G Athyros
    Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 20:1385-92. 2004
    ..This study demonstrated significant reductions in morbidity and mortality associated with active dose titration of atorvastatin and structured management of dyslipidaemia...
  19. ncbi request reprint Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study
    Vasilios G Athyros
    Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 18:220-8. 2002
    ..Atorvastatin is very effective in reducing plasma low-density lipoprotein cholesterol (LDL-C) levels. However, there is no long-term survival study that evaluated this statin...
  20. ncbi request reprint Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia--a pilot study
    V G Athyros
    Second Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 17:267-72. 2001
    ..These results require confirmation in larger studies...
  21. ncbi request reprint Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
    Vasilios G Athyros
    Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, 49 Konstantinoupoleos St, Thessaloniki, 546 42, Greece
    Curr Med Res Opin 18:499-502. 2002
    ..These findings may have cost implications, especially if the LDL-C target for high-risk patients will fall below those described above...
  22. ncbi request reprint Do we need to consider inflammatory markers when we treat atherosclerotic disease?
    Vasilios G Athyros
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece
    Atherosclerosis 200:1-12. 2008
    ..However, this concept requires proof in appropriately designed trials that include clinically relevant end points...
  23. ncbi request reprint Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis
    Vassilios G Athyros
    Lipid Out Patient, 2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    J Clin Gastroenterol 34:472-5. 2002
    ..Hypertriglyceridemia, usually severe, may be primary in origin or secondary to alcohol abuse, diabetes mellitus, pregnancy, and use of drugs...
  24. ncbi request reprint Effect of quinapril or metoprolol on circadian sympathetic and parasympathetic modulation after acute myocardial infarction
    A G Kontopoulos
    2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Am J Cardiol 84:1164-9. 1999
    ..Metoprolol had a similar effect during the late morning and evening hours, but at a lower level. These effects may prove beneficial in reducing cardiac arrhythmias and acute ischemic syndromes in past-AMI patients...
  25. ncbi request reprint The natural history of recently diagnosed autonomic neuropathy over a period of 2 years
    D T Karamitsos
    Diabetes Center, 2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Diabetes Res Clin Pract 42:55-63. 1998
    ..Indices of standard cardiovascular autonomic function tests and heart rate variability (HRV) are reliable markers of the presence and severity of DAN...
  26. ncbi request reprint Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy
    V G Athyros
    Division of Cardiology, Aristotelian University, Hippokration Hospital, Thessaloniki, Greece
    Acta Cardiol 53:201-9. 1998
    ....
  27. ncbi request reprint Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease
    V G Athyros
    Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    J Hum Hypertens 18:781-8. 2004
    ..Treatment with an ACEI in the absence of a statin use reduced clinical events in comparison to patients not treated with an ACEI but not significantly, at least in these small groups of patients...
  28. pmc The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study
    V G Athyros
    Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, 49 Konstantinoupoleos St, Thessaloniki, 546 42, Greece
    J Clin Pathol 57:728-34. 2004
    ....
  29. ncbi request reprint Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia
    Vasilios G Athyros
    Lipid Out patient Clinic, Division of Cardiology, 2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, 49 Konstantinoupoleos St, Thessaloniki, 546 42, Greece
    J Cardiovasc Risk 9:33-9. 2002
    ..Nonetheless, they have not been extensively used because of the fear of side effects. Thus, a therapeutic alternative is required for this lipid disorder...
  30. ncbi request reprint Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
    Vasilios G Athyros
    Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 20:627-37. 2004
    ....
  31. ncbi request reprint Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study
    Vasilios G Athyros
    Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Am J Kidney Dis 43:589-99. 2004
    ..Here, we report the time course of SUA levels in usual-care patients undertreated for their dyslipidemia (12% were administered statins) in comparison to structured-care patients treated with atorvastatin in the vast majority (98%)...
  32. ncbi request reprint Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus
    Vasilios G Athyros
    Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Angiology 54:679-90. 2003
    ..Clinical benefit is manifested as early as the sixth month of treatment...
  33. ncbi request reprint Statins and renal function in patients with diabetes mellitus
    Vasilios G Athyros
    Atherosclerosis Unit, Second Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 19:615-7. 2003
    ..Lipid lowering trials need to consider that changes in renal function may occur. Renal and ischaemic heart disease may progress in parallel and statins may be beneficial to both organs...
  34. doi request reprint Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis
    Vassilios G Athyros
    Department of Internal Medicine, Second Propedeutic Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Angiology 63:358-66. 2012
    ..Our findings suggest that treating the characteristics of MetS is achievable and beneficial. New-onset diabetes incidence and CVD events were negligible and not different from what is expected in the general population...
  35. ncbi request reprint Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women
    Vassilios G Athyros
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Curr Vasc Pharmacol 9:647-57. 2011
    ..To assess the reduction in estimated cardiovascular disease (e-CVD) risk after multifactorial treatment for 6 months and follow this change during the next 3-years...
  36. doi request reprint Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study
    Vassilios G Athyros
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
    Curr Med Res Opin 27:1659-68. 2011
    ..To assess the effects of long-term multifactorial intervention on renal function and serum uric acid (SUA) levels and their association with estimated cardiovascular disease (eCVD) risk and actual CVD events...
  37. ncbi request reprint Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluati
    Vasilios G Athyros
    FASA, FRSH, Department of Internal Medicine, Medical School, University of Ioannina, 451 10 Ioannina, Greece
    Nephrol Dial Transplant 22:118-27. 2007
    ..Metabolic syndrome (MetS) is associated with increased risk for both vascular and chronic kidney disease. Whether statins ameliorate these risks is not established...
  38. doi request reprint Blood pressure levels constitute the most important determinant of the metabolic syndrome in a Mediterranean population: a discrimination analysis
    Theodoros Chimonas
    Department of Internal Medicine, Medical School, University of Ioannina, Greece
    Metab Syndr Relat Disord 8:523-9. 2010
    ..The aim of the study was to evaluate the relative importance of the determinants of the metabolic syndrome in a sample with metabolic syndrome from the Greek population...
  39. ncbi request reprint Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
    Vasilios G Athyros
    Atherosclerosis and Metabolic Syndrome Units, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 22:873-83. 2006
    ..Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MetS). There is no established treatment for NAFLD...
  40. ncbi request reprint Dyslipidaemia, hypercoagulability and the metabolic syndrome
    Anna I Kakafika
    Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College Medical School, London, UK
    Curr Vasc Pharmacol 4:175-83. 2006
    ..Obesity and sedentary lifestyle coupled with genetic factors interact to produce the syndrome. Here, we consider two components of the metabolic syndrome, dyslipidaemia and hypercoagulability...
  41. ncbi request reprint Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort
    Vasilios G Athyros
    Atherosclerosis and Metabolic Syndrome Units, Aristotelean University, Hippocration Hospital, Thessaloniki, Greece
    Angiology 58:689-97. 2007
    ..Heavy drinking was associated with an increase in the prevalence of all of these disease states. Advice on alcohol consumption should probably mainly aim at reducing heavy drinking...
  42. ncbi request reprint Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options
    Konstantinos Tziomalos
    First Propedeutic Department of Internal Medicine, AHEPA Hospital, Thessaloniki, Greece
    Curr Vasc Pharmacol 10:162-72. 2012
    ..Accordingly, prevention of obesity and T2DM is of paramount importance for the reduction of the prevalence of NAFLD and of its associated cardiovascular and liver-related complications...
  43. pmc Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study
    Vassilios G Athyros
    2 Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece
    Arch Med Sci 7:796-805. 2011
    ..We assessed the long-term effects of multifactorial intervention on LFTs and their association with cardiovascular disease (CVD) events in patients with MetS without diabetes mellitus or CVD...
  44. doi request reprint Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome
    Theodoros Chimonas
    Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece
    Angiology 61:49-57. 2010
    ..This might justify local risk engine evaluation in event-based studies. (Clinical-Trials.gov ID: NCT00416741)...
  45. ncbi request reprint Serum uric acid as an independent predictor of early death after acute stroke
    Asterios Karagiannis
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
    Circ J 71:1120-7. 2007
    ..The prognostic significance of uric acid (UA) levels in acute stroke is unclear, so the objective of this study was to determine the association between levels of serum UA (SUA) and mortality in acute stroke...
  46. doi request reprint Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy
    Vasilios G Athyros
    Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Hippocration Hospital, Medical School, Thessaloniki, Greece
    Expert Opin Pharmacother 11:723-30. 2010
    ..In contrast, statins do not seem to decrease events in patients with advanced decline in kidney function...
  47. ncbi request reprint Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia
    Haralampos J Milionis
    Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece
    Am Heart J 148:635-40. 2004
    ..In addition to fenofibrate, there is some evidence that atorvastatin may have a hypouricemic action, but the underlying mechanisms remain speculative...
  48. doi request reprint Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis
    Vasilios G Athyros
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
    Lancet 376:1916-22. 2010
    ..We assessed whether statin therapy is safe and effective for these patients through post-hoc analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study population...
  49. ncbi request reprint Prevalence of vascular disease in metabolic syndrome using three proposed definitions
    Vasilios G Athyros
    Atherosclerosis and Metabolic Syndrome Units, 2nd Prop Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Int J Cardiol 117:204-10. 2007
    ..There are a number of definitions available for the diagnosis of the metabolic syndrome (MetS). The MetS-associated increase in cardiovascular disease (CVD) risk may depend on the definition used...
  50. ncbi request reprint Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients
    Vasilios G Athyros
    Atherosclerosis and Metabolic Syndrome Units, 2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Lipids 42:999-1009. 2007
    ..Statin (mainly atorvastatin)-induced decrease in TAG levels was related to a significant reduction in subsequent CVD events. This benefit was more pronounced in CHD MetS (+) patients...
  51. doi request reprint Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review
    Vassilios G Athyros
    Second Prop Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 29:1263-74. 2013
    ..In cases of inability to quit, measures to minimize the adverse effects of smoking specifically related to CVD should be taken. Smokers should receive best practice treatment, according to guidelines, as for non-smokers...
  52. ncbi request reprint Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients
    Athanasios G Kontopoulos
    Atherosclerosis Unit, Aristotelian University and Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 19:22-7. 2003
    ..To assess the effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients free of arterial hypertension and diabetes mellitus...
  53. ncbi request reprint Should atenolol still be recommended as first-line therapy for primary hypertension?
    Asterios Karagiannis
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
    Hellenic J Cardiol 47:298-307. 2006
  54. ncbi request reprint Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study
    Vasilios G Athyros
    Atherosclerosis and Metabolic Syndrome Units, Second Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 24:1593-9. 2008
    ..Reducing low-density lipoprotein cholesterol (LDL-C) levels to National Cholesterol Expert Panel (NCEP) goal is recommended. However, sex-specific effects may influence benefit...
  55. ncbi request reprint Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study
    Triantaffilos P Didangelos
    2nd Propeudetic Department of Internal Medicine, Division of Diabetology, Aristotelian University Medical School, Hippocration Hospital, Thessaloniki, Greece
    Diabetes Care 26:1955-60. 2003
    ..To investigate the relation between diabetic autonomic neuropathy (DAN) and left ventricular (LV) function in type 1 diabetic patients...
  56. ncbi request reprint Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures
    Kosmas I Paraskevas
    Department of Clinical Biochemistry Vascular Disease Prevention Clinic, Royal Free Hospital and Royal Free University College Medical School, London, UK
    Curr Drug Targets 8:942-51. 2007
    ..Future randomized trials are expected to further evaluate the beneficial effects of statins in these procedures...
  57. ncbi request reprint Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes
    Georgios Efstratiadis
    Department of Nephrology, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Angiology 57:303-11. 2006
    ..Given the cross-sectional design of the study, this finding should be confirmed by larger prospective and, it is hoped, interventional studies...
  58. ncbi request reprint Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy
    Triantafillos P Didangelos
    Diabetes Center, 2nd Propedeutic Clinic of Internal Medicine, Hippocration Hospital, Aristotelian University of Thessaloniki, 49 Konstantinoupoleos Street, 546 42 Thessaloniki, Greece
    J Diabetes Complications 20:1-7. 2006
    ....
  59. doi request reprint Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population
    Vasilios G Athyros
    Second Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 26:713-9. 2010
    ..The JIS definition was compared with three previous definitions to assess their ability to predict cardiovascular disease (CVD) risk...
  60. ncbi request reprint Atherogenesis in renal patients: a model of vascular disease?
    Georgios Efstratiadis
    Department of Nephrology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
    Curr Vasc Pharmacol 6:93-107. 2008
    ..Overall, the "later" stages of CKD may eventually be considered as a coronary heart disease equivalent condition...
  61. ncbi request reprint The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?
    Asterios Karagiannis
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
    Expert Opin Ther Targets 11:191-205. 2007
    ..There are differences among ARBs. Among them is the uricosuric effect of losartan. Furthermore, telmisartan may function as a partial agonist of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma)...
  62. ncbi request reprint Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?
    Asterios Karagiannis
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
    Curr Pharm Des 13:229-39. 2007
    ..This knowledge may help design drugs that are not only more effective in achieving blood pressure targets but that also markedly decrease vascular events...
  63. doi request reprint Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism
    Asterios Karagiannis
    Aristotle University of Thessaloniki, Second Propedeutic Department of Internal Medicine, Medical School, Hippokration Hospital, Thessaloniki, Greece
    Expert Opin Pharmacother 9:509-15. 2008
    ..It was concluded that eplerenone was as effective as spironolactone in reducing BP in patients with IHA. The risk of mild hyperkalaemia was similar with both drugs...
  64. ncbi request reprint Should adipokines be considered in the choice of the treatment of obesity-related health problems?
    Vasilios G Athyros
    Second Propedeutic Department of Internal Medicine, Aristotle University, Hippokration Hospital, Thessaloniki, Greece
    Curr Drug Targets 11:122-35. 2010
    ..Moreover, it summarises treatment options for the normalisation of adipokine levels, which might confer an additional clinical benefit in the effort to prevent or treat obesity-related T2DM and CVD...
  65. doi request reprint Lipoprotein a: where are we now?
    Konstantinos Tziomalos
    Department of Clinical Biochemistry Vascular Prevention Clinic, Royal Free Hospital Campus, University College Medical School, University College London, London, UK
    Curr Opin Cardiol 24:351-7. 2009
    ..To provide an update of the literature describing the link between lipoprotein a and vascular disease...
  66. ncbi request reprint High density lipoprotein cholesterol and statin trials
    Anna Kakafika
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
    Curr Med Chem 15:2265-70. 2008
    ..Whether a statin that beyond its LDL-C lowering effect also raises HDL-C has additional benefits in the prevention of vascular events remains to be established...
  67. ncbi request reprint Management of statin-intolerant high-risk patients
    Konstantinos Tziomalos
    Department of Clinical Biochemistry Vascular Prevention Clinic and Department of Surgery, Royal Free Campus, University College London Medical School, University College London UCL, London, UK
    Curr Vasc Pharmacol 8:632-7. 2010
    ..It is therefore difficult to make evidence-based recommendations for the management of this population. In addition, all treatment options have limitations in terms of safety and/or efficacy...
  68. ncbi request reprint Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?
    Vasilios G Athyros
    Aristotle University of Thessaloniki, Second Propedeutic Department of Internal Medicine, Medical School, Thessaloniki, Greece
    Expert Opin Pharmacother 8:2267-77. 2007
    ..However, the effective dose of aspirin may need to be at least 160 mg/day. This triple combination might improve patient compliance when compared with the three drugs administered separately...
  69. ncbi request reprint Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk?
    Panagiotis Anagnostis
    Endocrinology Clinic, Hippokration Hospital, Thessaloniki, Greece
    Curr Vasc Pharmacol 8:720-30. 2010
    ..This review considers current data regarding the role of vitamin D deficiency in the development of CVD and addresses the effect of supplementation on cardiovascular outcomes...
  70. ncbi request reprint Pheochromocytoma: an update on genetics and management
    Asterios Karagiannis
    Division of Endocrinology, Second Propedeutic Department of Internal Medicine, Medical School, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece
    Endocr Relat Cancer 14:935-56. 2007
    ..Furthermore, it emphasizes the need for genetic testing in cases with apparently sporadic PHEOs...
  71. ncbi request reprint Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels
    Vasilios G Athyros
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
    Curr Drug Targets 8:483-8. 2007
    ..HDL-C strategies, in combination with effective statins, are a new drug target aimed at a further reduction in CVD morbidity and mortality compared with statin monotherapy...
  72. doi request reprint Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?
    Efstathios D Pagourelias
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
    Angiology 60:74-81. 2009
    ..Nevertheless, more studies are needed and certain issues should be resolved, particularly the optimal hemoglobin level, before EPO can become part of the treatment of patients with CHF...
  73. ncbi request reprint Endocrine hypertension: diagnosis and management of a complex clinical entity
    Panagiotis Anagnostis
    Endocrinology Clinic, Hippokration Hospital, Thessaloniki, Greece
    Curr Vasc Pharmacol 8:646-60. 2010
    ..In addition, it is important to differentiate benign from malignant tumors. The present review provides an update on the pathophysiology and clinical presentation of EH. We also discuss the diagnostic work-ups and therapeutic strategies...
  74. ncbi request reprint Omega-3 fatty acids: how can they be used in secondary prevention?
    Konstantinos Tziomalos
    Second Propedeutic Department of Internal Medicine, Aristotle University, Hippokration Hospital, 63 Solonos Street, Thessaloniki, 54248, Greece
    Curr Atheroscler Rep 10:510-7. 2008
    ..Increased intake of EPA and DHA represents a valuable tool for vascular disease prevention and should be recommended in all patients with CHD...
  75. doi request reprint Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?
    Vasilios G Athyros
    Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 26:839-42. 2010
    ..This editorial discusses the results of statin loading trials and comments on the possible mechanisms involved...
  76. ncbi request reprint Is angioedema a class adverse effect of the angiotensin-converting enzyme inhibitors?
    Asterios Karagiannis
    Ann Allergy Asthma Immunol 98:502. 2007
  77. doi request reprint Additional effects of statins in surgical patients
    Kosmas I Paraskevas
    Ann Surg 248:140-1; author reply 141. 2008